For Physicians

Text

Placeholder text (you can add a block title above)

Custirsen (OGX-011) Phase 2 Clinical Trials Results

Our Phase 1 clinical trials evaluated the safety and established the recommended Phase 2 dose of OGX-011 in combination with either docetaxel chemotherapy (two different schedules), gemcitabine/cisplatin chemotherapy or hormone ablation therapy. In all clinical trials, 640 mg was established as the Phase 2 dose.

We have conducted five Phase 2 clinical trials of OGX-011 to further evaluate the safety and efficacy of OGX-011 in combination with various cancer therapies for prostate, non-small cell lung and breast cancer, as further described below.

Prostate Cancer

Final Results of Phase 2 Clinical Trial in Patients Receiving First-Line Chemotherapy Treatment for Castrate Resistant Prostate Cancer (OGX-011-03)

Phase 2 Clinical Trial - Hormone Ablation Therapy in Patients with Localized Prostate Cancer (OGX-011-04)

Preliminary Results of a Phase 2 Clinical Trial in Patients Receiving Second-Line Chemotherapy for Treatment of Hormone Refractory Prostate Cancer (OGX-011-07)

Lung Cancer

Preliminary Results of Phase 2 Clinical Trial in Patients Treated with First-Line Chemotherapy for Non-Small Cell Lung Cancer (OGX-011-05)

Breast Cancer

Preliminary Results of Phase 2 Clinical Trial in Patients with Advanced Breast Cancer (OGX-011-06)

This section is intended specifically for health care professionals. Information is provided for educational use only, based on pre-clinical and clinical data of curstirsen. Custirsen is not approved for commercial use and is only available for investigational use in approved clinical trials.

External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue